Vitasora Health (VHL) H2 2026 earnings summary

Executive summary

• FY26 marked a year of execution and transition, focusing on scaling a turnkey connected-healthcare platform and improving financial discipline.

• Migration to the proprietary vCare platform was completed, enhancing operational efficiency, billing productivity, and reducing software costs.

• Commercial momentum increased, with stronger daily billings and improved patient conversion metrics as the year progressed.

• The company deepened customer relationships, invested in U.S. operations, and strengthened its balance sheet through significant capital raising.

Financial highlights

• Customer receipts rose to A$3.97m, up from A$1.66m in FY25.

• Operating revenue increased to A$4.29m (FY25: A$3.09m); total revenue was A$4.84m.

• Loss after tax was A$10.61m, slightly improved from A$10.70m in FY25.

• Net operating cash outflows were A$10.00m (FY25: A$9.17m), with reductions in the second half due to efficiency gains.

• Cash at year end was A$3.06m, up from A$0.39m in FY25; net assets increased to A$16.13m.

Outlook and guidance

• FY27 priorities include completing platform consolidation, scaling the clinical team, deepening customer relationships, and progressing toward sustainable cashflow breakeven.

• Focus will shift from building infrastructure to extracting value, improving yield, and converting momentum into consistent cash generation.